Ads
related to: how to reduce hemophilia treatment options- Pain Management Info
Managing pain is possible.
Understanding pain & management.
- Bleeding Emergencies
Learn how you can prepare for
bleeding emergencies.
- Managing Dental Care
Oral and dental health matters.
Considerations for dental care.
- Active Lifestyle Benefits
Why moving more is a good move.
Bleeding disorders and exercise.
- Pain Management Info
Search results
Results from the WOW.Com Content Network
Hemophilia is a family of rare genetic blood diseases caused by a clotting factor deficiency (FVIII in hemophilia A, FIX in hemophilia B), impacting more than 800,000 people globally.
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. [5] [8] It is an anti-tissue factor pathway inhibitor. [5] [8] The most common adverse reactions include injection site reactions and hives (urticaria). [11]
It is a single-dose treatment that gives the patient the genetic information required to produce Factor IX. [91] In June 2023, the FDA approved the first gene therapy treatment for haemophilia A, called Roctavian. It was only approved for patients with severe cases, but it has been shown to reduce yearly bleeding episodes by 50%.
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.
Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII.These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.
Joint capsule. Haemophilia A's phenotype has a quite wide range of symptoms encompassing both internal and external bleeding episodes. Individuals with more severe haemophilia tend to experience more intense and frequent bleeding, whereas those with mild haemophilia typically exhibit milder symptoms unless subjected to surgical procedures or significant trauma.
For treatment of hemophilia A, recombinant factor VIII concentrates are available. For treatment of severe hemophilia B , recombinant factor IX concentrates are available. Crystalloid or colloid solutions such as human serum albumin or plasma protein fraction, are preferable to FFP for volume replacement.
Accredo Health Group, Inc. is a specialty pharmaceutical and service provider for patients with complex and chronic health conditions. [1] Accredo provides specialty drugs, drugs that cost more than $600 per month, with the average being $10,000 a month, which treat serious conditions such as multiple sclerosis, rheumatoid arthritis, hemophilia and cancer. [1]
Ads
related to: how to reduce hemophilia treatment options